Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRG-001
- Development stage
- Preclinical
- Lead developer
- Cothera Bioscience
- Modality
- Small Molecules
01
Overview
TRG-001 is a novel cytotoxic agent developed by Tragara Pharmaceuticals. It functions as a microtubule-targeting agent, designed for the treatment of multiple myeloma. The Multiple Myeloma Research Foundation (MMRF) provided a multi-year research grant to Tragara Pharmaceuticals to support the early-stage development of TRG-001.
Beyond the preview
Go deeper on TRG-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRG-001.